US 5,510,332 A · Process to inhibit binding of the integrin .alpha..sub.4 62 .sub.1 to VCAM-1 or fibronectin and linear peptides therefor

Abstract

The present invention is directed to an isolated and purified peptide comprising the LDV domain of the CSI peptide sequence or single amino acid substitutent analog thereof. A preferred peptide has the amino acid residue sequences shown in SEQ ID NOs:8-14, 17-23, 25, 28, and 51. The present invention is further directed to a process of inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1 or fibronectin comprising exposing a cell that expresses .alpha..sub.4 .beta..sub.1 integrin to the protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a peptide of SEQ ID NO:8-102.

Claims15

Dependent claims

An isolated and purified peptide of from 4 to about 13 amino acid residues having (a) an N-terminal amine group, acetyl group or a polyethylene glycol moiety of from about 400 to about 12,000 Daltons avemge molecular weight linked through an amide bond to the N-terminal residue;

and (b) a C-terminal carboxylic acid group or amide group;
said peptide comprising the amino acid residue sequence of SEQ ID NO:1 or a single amino acid substituent analog thereof, wherein the analog has the amino acid residue sequence of SEQ ID NO:2 or 3.

Dependencies are inferred from the claim text.

Process to inhibit binding of the integrin .alpha..sub.4 62 .sub.1 to VCAM-1 or fibronectin and linear peptides therefor

Life of this patent

Process to inhibit binding of the integrin .alpha..sub.4 62 .sub.1 to VCAM-1 or fibronectin and linear peptides therefor

Life of this patent

Abstract

Claims15